These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 30561569

  • 1. Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades.
    Forsman LD, Jonsson J, Wagrell C, Werngren J, Mansjö M, Wijkander M, Groenheit R, Hammar U, Giske CG, Schön T, Bruchfeld J.
    Clin Infect Dis; 2019 Sep 27; 69(8):1394-1402. PubMed ID: 30561569
    [Abstract] [Full Text] [Related]

  • 2. Characterization of pyrazinamide resistance in consecutive multidrug-resistant mycobacterium tuberculosis isolates in sweden between 2003 and 2015.
    Mansjo M, Werngren J, Hoffner S.
    Int J Mycobacteriol; 2017 Sep 27; 6(2):156-161. PubMed ID: 28559517
    [Abstract] [Full Text] [Related]

  • 3. Genotypic Resistance of Pyrazinamide but Not Minimum Inhibitory Concentration Is Associated With Longer Time to Sputum Culture Conversion in Patients With Multidrug-resistant Tuberculosis.
    Kuhlin J, Davies Forsman L, Mansjö M, Jonsson Nordvall M, Wijkander M, Wagrell C, Jonsson J, Groenheit R, Werngren J, Schön T, Bruchfeld J.
    Clin Infect Dis; 2021 Nov 02; 73(9):e3511-e3517. PubMed ID: 33011791
    [Abstract] [Full Text] [Related]

  • 4. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
    Yuen CM, Kurbatova EV, Tupasi T, Caoili JC, Van Der Walt M, Kvasnovsky C, Yagui M, Bayona J, Contreras C, Leimane V, Ershova J, Via LE, Kim H, Akksilp S, Kazennyy BY, Volchenkov GV, Jou R, Kliiman K, Demikhova OV, Vasilyeva IA, Dalton T, Cegielski JP.
    PLoS Med; 2015 Dec 02; 12(12):e1001932. PubMed ID: 26714320
    [Abstract] [Full Text] [Related]

  • 5. Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.
    Kuhlin J, Smith C, Khaemraev A, Tigay Z, Parpieva N, Tillyashaykhov M, Achar J, Hajek J, Greig J, du Cros P, Moore D.
    Int J Tuberc Lung Dis; 2018 May 01; 22(5):544-550. PubMed ID: 29663960
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
    Mok JH, Kang BH, Lee T, Lee HK, Jang HJ, Cho YJ, Jeon D.
    J Korean Med Sci; 2017 Apr 01; 32(4):636-641. PubMed ID: 28244290
    [Abstract] [Full Text] [Related]

  • 9. Pyrazinamide Resistance among Multidrug-Resistant Mycobacterium tuberculosis Clinical Isolates in Myanmar.
    Aung WW, Ei PW, Nyunt WW, Htwe MM, Win SM, Aye KT, Mon AS, Aung ST, Chang CL, Lee JS.
    Antimicrob Agents Chemother; 2018 Mar 01; 62(3):. PubMed ID: 29263056
    [No Abstract] [Full Text] [Related]

  • 10. Introducing molecular testing of pyrazinamide susceptibility improves multidrug-resistant tuberculosis treatment outcomes: a prospective cohort study.
    Sun F, Li Y, Chen Y, Guan W, Jiang X, Wang X, Ren P, Li J, Shi J, He G, Wu M, Tang P, Wang F, Sheng Y, Huang F, Zhou Z, Huang H, Hong L, Liu Q, Zhang Y, Zhang W.
    Eur Respir J; 2019 Mar 01; 53(3):. PubMed ID: 30578402
    [Abstract] [Full Text] [Related]

  • 11. Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan.
    Huang HT, Lin WH, Chan TH, Jou R.
    J Microbiol Immunol Infect; 2023 Dec 01; 56(6):1236-1244. PubMed ID: 37690869
    [Abstract] [Full Text] [Related]

  • 12. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC, Leung CC, Yew WW, Leung EC, Leung WM, Tam CM, Zhang Y.
    Antimicrob Agents Chemother; 2012 Nov 01; 56(11):5465-75. PubMed ID: 22869570
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis.
    Zheng X, Ning Z, Drobniewski F, Yang J, Li Q, Zhang Z, Hu Y.
    Int J Antimicrob Agents; 2017 Feb 01; 49(2):183-188. PubMed ID: 28012685
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Refining MDR-TB treatment regimens for ultra short therapy (TB-TRUST): study protocol for a randomized controlled trial.
    Weng T, Sun F, Li Y, Chen J, Chen X, Li R, Ge S, Zhao Y, Zhang W.
    BMC Infect Dis; 2021 Feb 17; 21(1):183. PubMed ID: 33596848
    [Abstract] [Full Text] [Related]

  • 19. Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.
    Walsh KF, Souroutzidis A, Vilbrun SC, Peeples M, Joissaint G, Delva S, Widmann P, Royal G, Pry J, Bang H, Pape JW, Koenig SP.
    Am J Trop Med Hyg; 2019 Feb 17; 100(2):392-398. PubMed ID: 30594266
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.